Key result
Dan Shen Di Wan (DS) significantly inhibited platelet aggregation, platelet-leucocyte conjugate formation, and leucocyte activation in response to multiple agonists (all p<0.01).
Why the study?
Does Dan Shen Di Wan inhibit platelet and leucocyte activation compared to conventional antiplatelet agents in vitro?
Does Dan Shen Di Wan inhibit platelet and leucocyte activation compared to conventional antiplatelet agents in vitro?
p-value: p=<0.01
The Chinese herbal formulation Dan Shen Di Wan and its extract SME demonstrate significant in vitro inhibition of platelet and leucocyte activation comparable to conventional antiplatelet agents.
Hypothesis-generating for Dan Shen Di Wan in platelet-leucocyte inhibition; prospective human trials required before any clinical consideration.
Platelet and leucocyte activity are important in the acute development of thrombosis and in the pathogenesis of ischaemic vascular disease. Dan Shen Di Wan (DS, Cardiotonic Pill or Dantonic(R) Pill) is one of the most commonly used Chinese herbal formulations for treating patients with atherosclerotic disease in China and several Asian countries. We studied the effect of DS on platelet and leucocyte function and compared the effects with conventional antiplatelet agents, cangrelor (ADP P2Y(12) receptor antagonist) and aspirin (acetyl salicylic acid, ASA). Measurements were made by platelet aggregation (%) and activation (CD62P %), platelet-monocyte conjugate formation (P/M, CD42a median fluorescence, mf), platelet-neutrophil conjugate formation (P/N, mf), and leucocyte activation (CD11b median fluorescence on monocytes and neutrophils, mf) in response to 3.3 micromol/L adenosine diphosphate (ADP), 1.0 micromol/L platelet activating factor (PAF), 5.0 micromol/L adrenaline and 0.5 microg/mL collagen. We also evaluated the effect of its main component, water soluble extract of salvia miltiorrhiza (SME) on intracellular calcium mobilization in platelets triggered by 10 micromol/L ADP, 10 micromol/L PAF, 2 microg/mL collagen and 15 micromol/L thrombin receptor activating peptide (TRAP). Overall DS showed inhibition of platelet aggregation, platelet activation, platelet-leucocyte conjugate formation and leucocyte activation in response to all the agonists apart from adrenaline (all p < 0.01). DS showed inhibition of platelet aggregation and leucocyte activation equivalent to cangrelor 100 nmol/L and ASA 100 micromol/L. SME dose-dependently inhibited intracellular calcium mobilization in platelets following stimulation with all the platelet agonists with maximum effective at 0.36 mg/mL (all p < 0.01). When used at 0.18 mg/mL its inhibitory effect was equivalent to cangrelor and ASA. We conclude that DS is a potential inhibitor of both platelet and leucocyte activation.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2008) studied Atherosclerotic disease. Dan Shen Di Wan (DS) vs. Cangrelor and aspirin was evaluated on Platelet aggregation, platelet activation, platelet-leucocyte conjugate formation, and leucocyte activation (p=<0.01). Dan Shen Di Wan (DS) significantly inhibited platelet aggregation, platelet-leucocyte conjugate formation, and leucocyte activation in response to multiple agonists (all p<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: